Moderna’s RSV shot 83.7% effective, late-stage trial shows
By Paige Twentier for Becker’s Hospital Review on January 18, 2023 Moderna’s respiratory syncytial virus vaccine candidate for older adults
Read moreBy Paige Twentier for Becker’s Hospital Review on January 18, 2023 Moderna’s respiratory syncytial virus vaccine candidate for older adults
Read moreBy Selena Simmons-Duffin for NPR on December 28, 2022 The U.S. has come a long way from two years ago
Read more